KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Chemed (CHE) EBITDA (2016 - 2026)

Chemed filings provide 18 years of EBITDA readings, the most recent being $98.9 million for Q1 2026.

  • For the quarter ending Q1 2026, EBITDA fell 8.62% year-over-year to $98.9 million, compared with a TTM value of $383.5 million through Mar 2026, down 13.23%, and an annual FY2025 reading of $392.8 million, down 6.33% over the prior year.
  • EBITDA hit $98.9 million in Q1 2026 for Chemed, down from $114.4 million in the prior quarter.
  • The five-year high for EBITDA was $127.1 million in Q4 2024, with the low at -$180.8 million in Q4 2022.
  • Median EBITDA over the past 5 years was $99.7 million (2023), compared with a mean of $83.6 million.
  • The largest YoY upside for EBITDA was 168.8% in 2023 against a maximum downside of 21.51% in 2023.
  • Year by year, EBITDA stood at -$180.8 million in 2022, then soared by 168.8% to $124.4 million in 2023, then rose by 2.19% to $127.1 million in 2024, then decreased by 10.01% to $114.4 million in 2025, then fell by 13.58% to $98.9 million in 2026.
  • According to Business Quant data, EBITDA over the past three periods came in at $98.9 million, $114.4 million, and $88.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.